 |
FOR IMMEDIATE RELEASE
TetraLogic Pharmaceuticals
COMPLETES $32 Million SERIES C FINANCING
Funds to Advance Novel SMAC Mimetic Cancer Drug Candidate through Phase 2a
Malvern, PA, August 10, 2010 – TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round. Also participating in the financing was new investor Hatteras Venture Partners and existing investors Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group. In conjunction with the financing, Michael Steinmetz, Ph.D., a Managing Director of Clarus Ventures, and Douglas Reed, M.D., a General Partner of Hatteras Venture Partners, have joined TetraLogic’s Board of Directors.
Proceeds from the financing will be used to advance clinical development of TL32711, TetraLogic’s lead drug candidate for the treatment of cancer. TL32711 is a SMAC mimetic that neutralizes the activity of inhibitor of apoptosis proteins (IAPs) that block tumor cell death. TL32711 is being evaluated in a Phase 1 study as a single agent in patients with solid tumors and lymphoma refractory to standard therapies.
“SMAC mimetics are a novel class of cancer therapeutics with the potential to enable treatment of solid and hematological cancers that would otherwise be resistant to therapy,” said Michael Steinmetz, Ph.D., Managing Director of Clarus Ventures. “We are encouraged by TL32711’s preclinical and early clinical data that it may fulfill the broad potential of an effective targeted pro-apoptotic therapy.”
“The support from our premier group of investors further validates our enthusiasm for the potential of TL32711 to treat cancer,” said John Gill, TetraLogic’s President and Chief Executive Officer. “We now have the resources to complete the ongoing single agent Phase 1a study, complete a Phase 1b/2a study of TL32711 in combination with several standard of care chemotherapies and to continue to develop and validate related biomarkers.”
About TL32711
TL32711 is a small molecule peptidomimetic of SMAC (an endogenous regulator of apoptotic cell death) that selectively antagonizes multiple inhibitor of apoptosis proteins (IAPs). Apoptosis, a process of programmed cell death, is the primary way that cancer cells are destroyed by standard therapies and also by the body’s biological responses to cancer. IAPs enable cancer cells to resist being destroyed. SMAC mimetics in preclinical studies have been shown to neutralize IAPs, and thus, overcome resistance and enable cancer cell destruction. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy and in combination with other anti-cancer therapies.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The Company’s most advanced SMAC mimetics neutralize selected IAPs to treat cancer. Earlier programs are focused on discovering and developing SMAC mimetics to treat certain autoimmune and inflammation related diseases and conditions.
TetraLogic’s investors include Amgen Ventures, Clarus Ventures, Hatteras Venture Partners, HealthCare Ventures, Kammerer Associates, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group. For additional information, please refer to the Company’s website at www.tetralogicpharma.com.
FOR IMMEDIATE RELEASE
TETRALOGIC PHARMACEUTICALS INITIATES PHASE 1 CLINICAL TRIAL OF TL32711 IN PATIENTS WITH REFRACTORY SOLID TUMORS OR LYMPHOMA
Malvern, PA – January 8, 2010 - TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
“This is an important milestone for our Company and for cancer patients,” said John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals. “The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
About TL32711
TL32711 is a synthetic, small molecule peptidomimetic of SMAC (an endogenous regulator of apoptotic cell death) that selectively antagonizes multiple Inhibitor of Apoptosis Proteins (IAPs). Apoptosis, a process of programmed cell death, is the primary way that cancer cells are destroyed by standard therapies and also by the body’s innate response to cancer. IAPs block apoptotic cell death enabling cancer to resist being destroyed by therapies and innate responses. SMAC mimetics in preclinical studies have been shown to neutralize the blocking activity of IAPs, and thus, overcome resistance and enable cancer cells to be destroyed. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy and in combination with other anti-cancer therapies.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The Company’s SMAC mimetics neutralize critical blocks in the apoptosis pathway to destroy cancer cells selectively. TetraLogic’s necrostatins are a first-in-class family of small molecule compounds that in preclinical studies selectively inhibit necrotic cell death and inflammation induced by multiple ligands at a crucial signal transduction pathway checkpoint. Necrostatins may enable cell survival in a wide range of diseases and injuries where necrosis and inflammation are critical components of pathology.
TetraLogic’s investors include HealthCare Ventures, Quaker BioVentures, Novitas Capital, Latterell Venture Partners, the Vertical Group, Amgen Ventures and Kammerer Associates. For additional information, please refer to the Company’s website at www.tetralogicpharma.com.
TETRALOGIC PHARMACEUTICALS LICENSES EXCLUSIVE RIGHTS TO NOVEL NECROSIS INHIBITORS FROM HARVARD MEDICAL SCHOOL
Malvern, PA – March 9, 2009 - TetraLogic Pharmaceuticals,
a privately held biopharmaceutical company, announced today
that the Company executed a license agreement under which
it acquired exclusive worldwide rights from Harvard University
to commercialize novel necrostatin compounds and related
drug discovery technology developed at Harvard Medical School. Necrostatins
are small molecule compounds that block a programmed cell
death process called necroptosis that would otherwise kill
cells by necrosis. Necroptosis and the potential effect of
necrostatins were originally discovered by Professor Dr.
Junying Yuan, a pioneer and a recognized leader in the field,
and Dr. Alexei Degterev, at the time a member of Dr. Yuan’s
lab at the Department of Cell Biology, Harvard Medical School.
Further improvement of necrostatin compounds was achieved
in collaboration with Dr. Greg Cuny of the Harvard NeuroDiscovery
Center Laboratory for Drug Discovery in Neurodegeneration.
Necrotic cell death occurs in the course of debilitating
acute and chronic conditions including neurological injuries,
neurodegenerative diseases, cardiovascular injuries, liver
and kidney diseases and injuries, burns, transplant rejections
and ocular diseases and injuries. Necrostatins have shown
potent activity in a variety of preclinical models representing
their possible clinical indications. TetraLogic intends
to commence human clinical studies of necrostatins during
mid-2010.
John M. Gill, President and Chief Executive Officer of TetraLogic
Pharmaceuticals, stated “Necrostatins have the potential
to treat debilitating diseases and conditions where current
therapies are inadequate or non-existent. We are excited
about translating this pioneering avenue of research into
important new drugs.” The necrostatin program
fits with capabilities of TetraLogic and its Inhibitor of
Apoptosis Proteins Antagonist program where the Company expects
to commence human clinical studies with a novel drug to treat
cancer during 2009.
"This agreement with TetraLogic marks an important
step forward for the development of necrostatins," said
Dr. Yuan. "Successful application of necrostatins for
human disease may prove transformative by providing new therapeutic
modalities for diseases that have no existing treatment."
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held company focused
on discovering and developing drugs that modulate cell
death pathways. To date, TetraLogic has raised a total
of $44 million through private financings. The Company’s
investors include Amgen Ventures, HealthCare Ventures,
Kammerer Associates, Latterell Venture Partners, Novitas
Capital, Quaker BioVentures and the Vertical Group. For
additional information, please refer to the Company’s
website at www.tetralogicpharma.com.
TETRALOGIC PHARMACEUTICALS APPOINTS DR. ANDREW PECORA
AS CHAIRMAN OF THE BOARD
Malvern, PA – May 6, 2008 - TetraLogic Pharmaceuticals, a privately held biopharmaceutical company announced today the appointment of Dr. Andrew Pecora, FACP, as Chairman of the Board. Dr. Pecora had served as a member of the Company’s Board of Directors since January 2007.
John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals, stated, “Drawing on his vast experience in hematology-oncology, cancer research and the business of healthcare, Dr. Pecora has contributed greatly as a member of the Board since his appointment last year. He has become actively involved in our IAP antagonist program and working with me on our company strategy. We look forward to continuing to work closely with Dr. Pecora.”
“During the past year I have become confident thatSmac Mimetics can be a major advancement in treating cancer patients,” stated Dr. Pecora. “As I watched TetraLogic’s program progress I decided I wanted to become more actively involved. When the Board asked me to consider the position of Chairman, I gratefully agreed.”
Dr. Pecora provides TetraLogic with a wealth of expertise in the field of hematology and oncology, cancer research, novel therapeutic development and clinical trial design. Under his leadership, the Hackensack University Cancer Center has become one of the top cancer centers in the United States. Dr. Pecora has spent the past 18 years in various capacities at Hackensack University Medical Center, currently serving as Chairman and Executive Administrative Director of The Cancer Center. He also serves as Chairman and was a founder of Amorcyte, Inc., a company developing cell therapies for cardiovascular disease and as Chairman and CEO of a cell therapy manufacturing and services company, Progenitor Cell Therapy, LLC.
Dr. Pecora has authored and co-authored numerous articles, abstracts, books, chapters and monographs and is a frequent lecturer in the field of cancer. Prior to joining Hackensack Medical Center he was a hematology-oncology Fellow at Memorial Sloan-Kettering Cancer Center in New York. Dr. Pecora is licensed to practice Medicine in both New Jersey and New York and is a Professor of Medicine at UMDNJ.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held company focused on discovering and developing drugs that modulate cell death pathways. Its lead program,Smac Mimetics to treat cancer, is in preclinical development. Other cell death pathway drug discovery programs are at an earlier stage of development. To date, TetraLogic has raised a total of $44 million through private financings. The Company’s investors include Amgen Ventures, HealthCare Ventures, Kammerer Associates, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group. For additional information, please refer to the Company’s website at www.tetralogicpharma.com.
TETRALOGIC PHARMACEUTICALS APPOINTS DR. ANDREW PECORA
TO ITS BOARD OF DIRECTORS
Malvern, PA - January 30, 2007 - TetraLogic Pharmaceuticals, a privately held company specializing in the discovery and development of oncology therapeutics, announced today that, effective immediately, Dr. Andrew Pecora, FACP, has joined the Company’s Board of Directors, bringing the Board to seven members.
John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals, stated, “We are delighted to welcome Dr. Pecora to our Board. He brings to our organization a wealth of expertise in the field of hematology-oncology and cancer research, including clinical trial design, and is a pioneer in the use of Granulocyte Cell Stimulating Factor (GCSF) for the supportive care of cancer patients. Additionally, under his leadership, the Hackensack University Cancer Center, where he is presently Chairman and Executive Administrative Director, has become one of the top cancer centers in the United States. As Founder of two life sciences companies, Dr. Pecora also brings welcome experience in business development. We look forward to numerous contributions by Dr. Pecora as TetraLogic Pharmaceuticals moves from the pre-clinical to clinical stages of product development, and beyond.”
Dr. Pecora is currently in private practice in Hackensack, NJ. In addition, he has spent the last 18 years in various capacities at Hackensack University Medical Center in Hackensack, NJ, currently serving as Chairman and Executive Administrative Director of The Cancer Center, Senior Scientist at the Institute for Biomedical Research, and Attending Physician of Internal Medicine, Member, Section of Hematology-Oncology. During his tenure at Hackensack University Medical Center, Dr. Pecora has also held the roles of Chairman and Director of The Cancer Center; Director, Hematology and Medical Oncology; Chief, Adult Blood and Marrow Stem Cell Transplant Service; and Medical Director, Stem Cell Collection and Storage Service, among others.
Among his numerous other professional positions, Dr. Pecora is co-Founder and co-managing partner of Northern New Jersey Cancer Associates. He is also founder and Chairman of Amorcyte, Inc., a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, and Co-founder, Chairman and Chief Executive Officer of Progenitor Cell Therapy, LLC, a client-based cell therapy services company supporting the development and commercialization of cellular therapies. Dr. Pecora also currently serves as Editor of the American Society of Blood and Marrow Transplantation e-News; a Member of the Medical Advisory Board of The Bone Marrow Foundation; and Member, New Jersey Working Group to Improve Outcomes in Cancer Patients.
Dr. Pecora has authored or co-authored numerous articles, abstracts, books, chapters and monographs and is a frequent lecturer in the field of cancer. He received his Bachelor of Science degree in Biology from Seton Hall University and his Medical Degree from the University of Medicine and Dentistry of New Jersey. He completed both his postdoctoral internship in internal medicine as well as his residency in the Department of Internal Medicine at The New York Hospital, located in New York, NY, and completed a fellowship in hematology-oncology at Memorial Sloan-Kettering Cancer Center, also in New York. He is licensed to practice in both New Jersey and New York.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held company focused on discovering and developing new oncology drugs. Its lead program,Smac Mimetics, are in preclinical development and are slated to enter clinical trials during the second half of 2007. Other apoptosis related drug discovery programs are at an earlier stage of development. To date, TetraLogic has raised a total of $44 million through private financings. The Company’s investors include Amgen Ventures, HealthCare Ventures, Kammerer Associates, Latterell Venture Partners, PA Early Stage Partners, Quaker BioVentures and the Vertical Group. For additional information, please refer to the Company’s website at www.tetralogicpharma.com.
TETRALOGIC PHARMACEUTICALS
COMPLETES $36 MILLION SERIES B FINANCING
Funds to Advance IAP Antagonist Oncology Program into Clinic
Malvern, PA – June 12, 2006 – TetraLogic Pharmaceuticals, a privately held company specialized in discovery and development of oncology therapeutics, announced today that it has completed a $36 million Series B private equity financing. Proceeds from the financing will be invested to advance its Inhibitor of Apoptosis Proteins (IAP) antagonist oncology program through initial clinical trials. The financing was led by San Francisco based Latterell Venture Partners. Also included are new investors, Quaker BioVentures, the Vertical Group and Amgen Ventures, and TetraLogic’s existing investors, HealthCare Ventures, PA Early Stage Partners and Kammerer Associates.
TetraLogic Pharmaceuticals is developing small molecules based on discoveries that underpin the design and synthesis ofSmac Mimetics that drive cancer cells towards destruction by apoptosis, or programmed cell death. “The Series B financing and our investor group provide the resources we need to advanceSmac Mimetics into the clinic and build a successful company,” stated John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals. “We’re more than pleased with the quality and support of our new and existing investors.”
Dr. Larry A. Lasky, a partner of Latterell Venture Partners said, “TetraLogic’sSmac Mimetics could improve treatment of a wide variety of cancers by removing a fundamental defense mechanism that cancer cells use to survive. I’m looking forward to seeing these promising new drugs get to patients as soon as possible.”
Dr. Brenda D. Gavin, a Quaker BioVentures partner said, “We’ve watched the Company progress since inception and have known its management for many years. This is another high quality Philadelphia based life sciences company and we look forward to working with the team to help it build success.”
Concurrent with closing the Series B financing, Dr. Lasky, Dr. Gavin and Mr. Jack W. Lasersohn, J.D., partner of The Vertical Group, will join Harold Werner of Healthcare Ventures LLC, Paul Schmitt of PA Early Stage Partners, and Mr. Gill on TetraLogic’s Board of Directors.
About Apoptosis and Inhibitor of Apoptosis Protein (IAP) Antagonists
Apoptosis is a specialized process by which cells are instructed to die. Cancer cells often escape from apoptosis and survive by creating an imbalance of proteins involved in controlling apoptosis. One important class of these proteins is called Inhibitor of Apoptosis Proteins (IAPs). TetraLogic’sSmac Mimetics are small molecules designed to overcome cancer cells’ escape mechanism and promote selective killing of these malignant cells. In preclinical studies,Smac Mimetics show the potential to treat many types of cancer when administered alone or in combination with other cancer therapies.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held company focused on discovering and developing new oncology drugs. Its lead program,Smac Mimetics are in preclinical development and are slated to enter clinical trials during the second half of 2007. Other apoptosis related drug discovery programs are at an earlier stage of development. TetraLogic completed an $8 million Series A financing led by Healthcare Ventures during March 2004. For additional information, please refer to the Company’s website at www.tetralogicpharma.com.
Malvern, Pennsylvania – June 29, 2004 – TetraLogic Pharmaceuticals, an emerging biopharmaceutical company focused on the development of breakthrough pharmaceutical products for treating HIV infection and cancer, today announced that it has relocated from Princeton, New Jersey and established its headquarters and research and development operations in Malvern, Pennsylvania.
“We are proud to become part of a new wave of outstanding biotech companies that have recently emerged in the Greater Philadelphia region. The region has a wealth of resources: leading medical research institutions; premier biotechnology and pharmaceutical companies; experienced investors; and ample scientific and management talent.” said John Gill, TetraLogic’s President and Chief Executive Officer. “The state’s commitment to life sciences companies combined with the alignment of support from Pennsylvania Bio and other regional support organizations have created significant momentum. There’s something good happening here and now we’re part of it.”
TetraLogic’s products will be based on novel proprietary biology and chemistry. The technologies focus on a common theme of enabling cancer and HIV infected cells to die through the process of programmed cell death “We have a real head start in our cancer program based on the work of our founding scientists at Princeton University,” said Dr. Mark McKinlay, TetraLogic’s Chief Scientific Officer. “The program is exciting because the drugs we develop may be useful for many different types of cancer and we should be able to use a laboratory test to pre-select patients most likely to respond to therapy”.
TetraLogic recently closed an $8 million start-up financing. The financing was led by HealthCare Ventures LLC of Princeton, New Jersey and PA Early Stage of Wayne, Pennsylvania. PA Early Stage is one of the biotech venture capital firms that received tobacco settlement investment dollars to be invested Pennsylvania life sciences companies. The Tobacco Settlement Investment Board is managed by the Technology Investment Office of the Pennsylvania Department of Community and Economic Development.
“During the early to mid 1980’s the region created two of the nation’s biggest biotech company successes – Centocor and Cephalon. A decade later, successful companies like Adolor, 3 Dimensional Pharmaceuticals and others emerged, creating jobs for thousands of Pennsylvanians,” said Dennis Yablonsky, Secretary of the Pennsylvania Department of Community and Economic Development. “Building on its past success, the region is creating an impressive new crop of start-up companies – companies like TetraLogic, BioRexis, Eximias, Acuity, Nucleonics, Morphotek and others.”
Yablonsky went on to note that most managers in these companies have previously worked both in the region’s major pharmaceutical companies and biotechnology companies, creating a collaborative environment. “The state expects these new companies to make major contributions to healthcare and to the region’s economy and we are pleased to see our efforts and investments paying off,” said Yablonsky.
|
|
